Tumor treating fields as novel combination partner in the multimodal treatment of head and neck cancer.

We aimed to demonstrate the effects of tumor treating fields (TTFields) in head and neck squamous cell carcinoma (HNSCC) cells when combined with radiotherapy (RT) and chemotherapy. Two human HNSCC cell lines (Cal27, FaDu) received five different treatments: TTFields, RT +/- TTFields and RT + simultaneous cisplatin +/- TTFields. Effects were quantified using clonogenic assays and flow cytometric analyses of DAPI, caspase-3 activation and γH2AX foci. Treatment with RT + TTFields decreased the clonogenic survival as strong as treatment with RT + simultaneous cisplatin. The triple combination of RT + simultaneous cisplatin + TTFields even further decreased the clonogenic survival. Accordingly, combination of TTFields with RT or RT + simultaneous cisplatin increased cellular apoptosis and DNA double-strand breaks. TTFields therapy seems a promising combination partner in the multimodal treatment of locally advanced HNSCC. It could be used to intensify chemoradiotherapy or as alternative to chemotherapy. © 2023 The Authors. Head & Neck published by Wiley Periodicals LLC.

Citation

Sebastian Regnery, Henrik Franke, Thomas Held, Thuy Trinh, Ariel Naveh, Yissachar Abraham, Juliane Hörner-Rieber, Jochen Hess, Peter E Huber, Jürgen Debus, Ramon Lopez Perez, Sebastian Adeberg. Tumor treating fields as novel combination partner in the multimodal treatment of head and neck cancer. Head & neck. 2023 Apr;45(4):838-848

Mesh Tags

Substances

PMID: 36872620

search → result